
TSVT
2Seventy Bio Inc
- Overview
- Forecast
- Valuation
- Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
193.28M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
51.41M
EV
95.77M
EV/OCF(TTM)
--
P/S(TTM)
5.51
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
18.90M
+545.93%
--
--
16.50M
+21.94%
--
--
13.43M
+49.79%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for 2seventy bio, Inc. (TSVT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 0.40%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Up

+0.40%
In Past 3 Month
2 Analyst Rating

Wall Street analysts forecast TSVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSVT is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
2 Hold
0 Sell
Hold

Current: 0

Low
5.00
Averages
5.00
High
5.00

Current: 0

Low
5.00
Averages
5.00
High
5.00
Morgan Stanley
Matthew Harrison
Hold
Maintains
$6 → $5
2025-03-14
Reason
Morgan Stanley
Matthew Harrison
Price Target
$6 → $5
2025-03-14
Maintains
Hold
Reason
Morgan Stanley lowered the firm's price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following 2Seventy Bio's recent announcement to be acquired by Bristol Myers (BMY). The firm expects an on-time transaction close in Q2 at the proposed transaction price.
Leerink Partners
Daina Graybosch
Buy
to
Hold
Downgrades
$9 → $5
2025-03-11
Reason
Leerink Partners
Daina Graybosch
Price Target
$9 → $5
2025-03-11
Downgrades
Buy
to
Hold
Reason
Morgan Stanley
Matthew Harrison
Hold
Maintains
$7 → $6
2024-07-29
Reason
Morgan Stanley
Matthew Harrison
Price Target
$7 → $6
2024-07-29
Maintains
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for 2Seventy Bio Inc (TSVT.O) is -23.76, compared to its 5-year average forward P/E of -3.54. For a more detailed relative valuation and DCF analysis to assess 2Seventy Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.54
Current PE
-23.76
Overvalued PE
-0.74
Undervalued PE
-6.35
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.56
Current EV/EBITDA
-8.00
Overvalued EV/EBITDA
-1.07
Undervalued EV/EBITDA
-4.04
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
4.76
Current PS
4.12
Overvalued PS
7.24
Undervalued PS
2.28
Financials
Annual
Quarterly
FY2025Q1
YoY :
+84.46%
22.94M
Total Revenue
FY2025Q1
YoY :
-94.81%
-2.46M
Operating Profit
FY2025Q1
YoY :
-100.92%
482.00K
Net Income after Tax
FY2025Q1
YoY :
-100.99%
0.01
EPS - Diluted
FY2025Q1
YoY :
-74.17%
-10.97M
Free Cash Flow
FY2025Q1
YoY :
+5.20%
77.54
Gross Profit Margin - %
FY2025Q1
YoY :
-52.53%
-112.04
FCF Margin - %
FY2025Q1
YoY :
-100.50%
2.10
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 21485.15% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
80.1M
USD
5
6-9
Months
378.5K
USD
10
0-12
Months
33.8K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 870.15% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.0M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
1.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 21485.15% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
80.1M
USD
5
6-9
Months
378.5K
USD
10
0-12
Months
33.8K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TSVT News & Events
Events Timeline
2025-03-25 (ET)
2025-03-25
16:06:48
2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

2024-12-03 (ET)
2024-12-03
04:10:26
Regeneron pays $1M milestone payment to Medigene

2024-11-12 (ET)
2024-11-12
06:39:36
2seventy Bio reports Q3 EPS (19c), consensus (24c)

Sign Up For More Events
Sign Up For More Events
News
7.0
04-16PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BHLB, TSVT, RDFN on Behalf of Shareholders
9.0
04-01NASDAQ.COMCHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
3.0
03-23NASDAQ.COM$TSVT Earnings Preview: Recent $TSVT Insider Trading, Hedge Fund Activity, and More
Sign Up For More News
People Also Watch

OPTT
Ocean Power Technologies Inc
0.643
USD
-14.84%

CMT
Core Molding Technologies Inc
17.420
USD
+1.40%

LPTH
LightPath Technologies Inc
3.060
USD
-4.38%

XNET
Xunlei Ltd
4.950
USD
-0.80%

CEP
Cantor Equity Partners Inc
28.190
USD
-2.73%

DIBS
1stdibs.Com Inc
2.690
USD
-2.18%

NEON
Neonode Inc
27.340
USD
-5.46%

VEEA
Veea Inc
1.640
USD
+0.61%

CABA
Cabaletta Bio Inc
1.660
USD
0.00%

QRTEA
Qurate Retail Inc
0
USD
-0.28%
FAQ

What is 2Seventy Bio Inc (TSVT) stock price today?
The current price of TSVT is 0 USD — it has increased 0.2 % in the last trading day.

What is 2Seventy Bio Inc (TSVT)'s business?

What is the price predicton of TSVT Stock?

What is 2Seventy Bio Inc (TSVT)'s revenue for the last quarter?

What is 2Seventy Bio Inc (TSVT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for 2Seventy Bio Inc (TSVT)'s fundamentals?

How many employees does 2Seventy Bio Inc (TSVT). have?
